Objective: To determine the hypoalgesic effects of transcutaneous electrical nerve stimulation (TENS) parameter combinations on experimental models in healthy humans.
T ranscutaneous electrical nerve stimulation (TENS) may be defined as the application of electrical stimulation to the skin for purposes of pain control. 1 TENS is used in many painful conditions (eg, osteoarthritis, rheumatoid arthritis, and neck pain). 2 Commonly described TENS modes are based on parameter (setting) combinations thought to activate different nerve fibers. Strong and comfortable TENS (usually without muscle contraction) and high frequencies [10 to 200 pulses per second (pps)] with electrodes applied over the painful area, termed "conventional TENS," may activate Ab fibers. Stimulation of this type has been shown to modulate pain at a spinal/ segmental level 3, 4 in accordance with the gate control theory. 5 Strong and uncomfortable TENS (with muscle contraction) and low frequencies (below 5 pps), often termed "acupuncture-like TENS," may activate Ad fibers. During acupuncture-like TENS, bursts of pulses are often used with electrodes applied predominantly over the painful area although acupuncture and trigger point sites are used. "Intense TENS" is also delivered at strong and uncomfortable levels over the painful area, but with high frequencies (10 to 200 pps), these setting also activate Ad fibers. TENSinduced activity in Ad fibers may modulate pain by longterm depression of nociceptive pathways 6 or descending inhibitory pain pathways. 7, 8 Meta-analyses of RCTs where TENS is delivered at strong, near-noxious intensities combined with pulse frequencies between 1 and 150 pps show superior efficacy to placebo TENS in trials of postoperative pain 9 and osteoarthritis of the knee. 10 Such findings suggest that a rethink of traditional parameter combinations frequently cited in the literature, educational texts, and manufacturers' user manuals is required. The clear support from these studies for a dose-specific response stands in contrast to the conflicting evidence emerging from other systematic reviews. 11 There is a need for evidence-based TENS dosages to be developed for use in clinical RCTs. 11 By analogy with phase 2 trials for pharmaceutical agents, these evidence-based protocols may be informed by doserelated responses from experimental pain trials in healthy humans.
A recent review concluded that TENS frequency (with all other parameters held constant) does not influence hypoalgesia using experimental pain models in healthy humans. 12 In this review, trials were included if they compared TENS doses with each other. This is not the primary aim of randomized controlled trials (RCTs) investigating efficacy and trials are therefore not usually powered for such comparisons. The aim of this review was therefore to determine the hypoalgesic efficacy of different TENS parameter combinations on experimental pain models in healthy humans compared with an inactive control group, from methodologically robust RCTs.
MATERIALS AND METHODS
The electronic databases Ovid MEDLINE, CINAHL, AMED, and Web of Science were searched (1966 to December 2009). Terms for TENS (electric stimulation therapy OR TENS OR transcutaneous electric nerve stimulation) were combined with "humans" and "pain" to search these databases. Specific journals (Pain, Clin J Pain, Physiother Theory Pract, and Arch Phys Med Rehabil) and the reference lists of retrieved trials were also manually searched. 13 Trials were included if they were RCTs conducted on healthy humans that compared TENS (using various parameters) with placebo and control, using an experimental pain model, with pain (intensity, threshold, or tolerance) as the primary outcome measure. Trials were excluded if: TENS was applied orally or auricularly, another type of electrical stimulation (eg, interferential) was used, TENS was not the only active intervention, or they were not published in English.
Two reviewers performed independent screening of the citations, data extraction, and quality assessment. Disagreements were resolved by discussion. Standardized forms were used to extract data concerning trial characteristics, interventions, and outcomes. The quality of trials was assessed using the Jadad et al 14 scale (Table 1 ). This scale was chosen because it includes items (blinding and randomization) that have been shown to affect the internal validity of studies. 16, 17 However, item #5, concerning participant withdrawal and dropouts, may be irrelevant to TENS experimental trials under consideration as such trials usually involve a single experimental session that does not provide much opportunity for attrition; consequently, the tool may result in a score that overrates the trial's quality. This item was therefore replaced by a measure of statistical power, which is a key issue for methodologically robust efficacy trials. Trials were classified as either adequately or inadequately powered in terms of their ability to detect a "large" pair-wise effect-that is Z0.8
15 -with at least 80% power (Table 1) . We explored the effects of both individual Jadad scale items and the summary Jadad score scale on the results of the review. 18, 19 A trial was rated as high quality (Z3 or more points out of 5) or low quality (r2 points). 20 Data were extracted concerning TENS intensity ("just perceptible," "strong but comfortable," or "strong and uncomfortable but not painful"), frequency [low (r10 pps) or high (>10 pps)], 21 stimulation site [local (painful area/ segmental), remote (extrasegmental), or both local and remote (concurrent) to the pain site], and timing of outcome measurement (TENS switched on, switched off, or only poststimulation monitoring). Trials were also scored as having an "appropriate" or "inappropriate" delivery of TENS. An appropriate delivery of TENS was defined as: TENS delivered so that the patient reports a "strong" sensation (with or without a tetanic and visible muscle contraction), pulse duration 50 ms to 2 ms, in the frequency range 1 to 250 pps, using a continuous or modulated pattern, applied over the pain site, nerve bundles of the pain site, 22 or remote to the pain site. TENS parameters were also subsequently categorized into the commonly described TENS modes: conventional TENS, acupuncture-like TENS, and intense TENS, where appropriate.
The outcome of each trial was determined in relation to the primary outcome measure. If a significant difference was reporting favoring TENS at any time point in relation to the primary outcome measure, the trial was deemed to be a positive trial. To determine the efficacy of TENS, trials were categorized as follows: (1) if a significant difference favored TENS ("positive" trial), (2) if a significant difference favored the control group, or (3) if there was no significant difference between TENS and the control group ("negative" trial). A best-evidence synthesis 23 was used to summarize the results of the included RCTs. The level of evidence was dependent on the findings of the RCTs and the quality. The level of evidence was ranked (and will subsequently be reported) according to the following criteria 24 : Strong evidence-provided by generally consistent findings in multiple high-quality RCTs; "Moderate" evidence-provided by generally consistent findings in 1 high-quality RCT plus 1 or more low-quality RCTs, or by generally consistent findings in multiple lowquality RCTs; "Limited" or "conflicting" evidence-only 1 RCT (either high or low quality) or inconsistent findings in multiple RCTs; "No evidence"-no RCTs.
Where a significant difference favored TENS, TENS was regarded as having efficacy. Where a significant difference favored the control group or there was no significant difference between TENS and the control group, then TENS was regarded as having inefficacy. Therefore, the levels of evidence will be reported for both TENS efficacy and inefficacy. To determine the size of any TENS effect, effect sizes were calculated for each experimental group at appropriate time points as follows:
control group mean À experimental group mean pooled baseline standard deviation Effect sizes were deemed small (0.3 to 0.49), medium (0.5 to 0.79), or large (0.8 and above). 25 Owing to the differences in trial characteristics and the variety of both the outcome measures and TENS parameters used, a metaanalysis was not deemed to be feasible, and data were therefore not combined. The primary analysis investigated the effects of TENS compared with inactive control groups irrespective of the TENS parameters used. Subgroup analyses were carried out to determine the effects of different TENS parameter combinations (inappropriate TENS and appropriate TENS: conventional TENS, acupuncture-like TENS, intense TENS, and low-frequency low-intensity TENS) compared with inactive control groups.
RESULTS
Forty-three RCTs were eligible for inclusion, and 48 trials were excluded (Fig. 1) . The outcomes and methodologic quality of the 43 included RCTs are reported in Table 2 . On 2 occasions, 2 RCTs were published in 1 article. 26, 49 Overall, TENS showed conflicting evidence of efficacy. Twenty-four trials reported positive outcomes 28 
Timing of Outcome Measurement
There is conflicting evidence whether the timing of outcome measurement influences the assessment of hypoalgesic response. 
TENS Parameter Combinations Inappropriate TENS Delivery
There is moderate evidence of inefficacy of inappropriate TENS doses. Five low-quality trials investigated TENS parameters which did not satisfy the appropriate TENS criteria. [28] [29] [30] [31] [32] These included just perceptible intensities and a small pulse width (Table 3) . Four (80%) [29] [30] [31] [32] of these 5 trials reported negative outcomes of TENS compared with an inactive control. Four (80%) low-quality trials reported negative outcomes [29] [30] [31] [32] [7 intervention groups (n=80) and 4 control groups (n=46)]; and 1 low-quality trial reported positive outcomes 28 [2 intervention groups (n=24) and 1 control group (n=12)].
Appropriate TENS Delivery
TENS Modes: Thirty-six trials were scored as having appropriate TENS delivery; the remaining 2 trials 51,61 did not report sufficient information (omitted pulse durations) to achieve a grading and are therefore not included in the subgroup analyses (Table 3) . Subjective intensity descriptions were used as interpretations of applied intensity as only 10 trials 27, 31, [39] [40] [41] [42] 54, 56, 58 reported the milliamperes (mA) applied and only 5 trials 26,33,55,58,63 noted whether or not a muscle contraction was observed.
Intense TENS: There is moderate evidence of efficacy of intense TENS. This TENS mode was investigated by 4 trials, 31, 37, 58, 65 of which 1 was high quality and 3 were low quality. Three (75%) 37, 58, 65 trials (including a high quality and adequately powered trial 37 ) reported positive outcomes.
The evidence for efficacy of intense TENS is predominantly limited across different experimental pain models. There is limited evidence of efficacy of this TENS mode on pressure pain [1 high-quality trial 37 ; 1 intervention group (n=30) and 2 control groups (n=60)], cold pressor pain [1 low-quality trial 58 ; 2 intervention groups (n=24) and 1 control group (n=12)], and CO 2 laser pain [1 lowquality trial 65 ; 1 intervention group (n=10) and 1 control group (n=10)]. There is, however, limited evidence of inefficacy of this TENS mode on ischemic pain [1 lowquality trial 31 ; 2 intervention groups (n=20) and 1 control group (n=10)].
Low-frequency low-intensity local TENS: There is strong evidence of the inefficacy of low-frequency, lowintensity, local TENS. This mode of TENS was investigated by 15 trials, 26, 33, 35, 37, 42, 46, 47, 49, 54, 59, 60, 64, 66 of which 3 (20%) 33, 49, 64 reported positive outcomes and 12 (80%) 26, 35, 37, 42, 46, 47, 49, 54, 59, 60, 66 reported negative outcomes. Only 1 of these 3 positive trials was high quality 33 compared with 8 high-quality negative trials. 26, 37, 42, 46, 47, 59, 60 The inefficacy of low-frequency low-intensity local TENS varies widely across different experimental pain models. There is strong evidence of inefficacy of this TENS mode for pressure pain from 5 negative trials [4 high quality 37, 42, 46, 47 and 1 low quality 35 ; 8 intervention groups (n=102) and 8 control groups (n=119), and from 1 lowquality positive trial 49 (1 intervention group (n=16) and 1 control group (n=16)]. Similarly, there is strong evidence of its inefficacy for the RIII pain model [2 high-quality negative trials 59, 60 ; 3 intervention groups (n=36) and 2 control 2) The method to generate the sequence of randomization was described and it was appropriate (table of random Scoring for the Jadad Scale: items 1+2+3+4+5=5 possible points; 0-2=low quality and 3-5=high quality. In the modified scale, item 5 is omitted and replaced with the statistical power item; 0-2=low quality and 3-5=high quality.
N indicates no; Y, yes.
groups (n=22)]. There is moderate evidence of inefficacy of this TENS mode on cold pressor pain [2 low-quality trials 26, 54 ; 2 intervention groups (n=19) and 3 control groups (n=29)] and conflicting evidence of inefficacy on ischemic pain [1 high-quality positive trial 33 ; with 1 intervention group (n=8) and 2 control groups (n=16), and 1 high-quality negative trial 26 ; with 2 intervention groups (n=16) and 2 control groups (n=16)]. There is also limited evidence of inefficacy of this TENS mode on delayed-onset muscle soreness (DOMS) [ reported negative outcomes. One positive trial 42 and 1 negative trial 38 were rated as high quality; although the negative trial was adequately powered, the positive trial was not.
The efficacy of acupuncture-like TENS varies from conflicting efficacy to moderate inefficacy across different experimental pain models. The efficacy of this mode of TENS is conflicting on pressure pain [1 positive highquality trial 42 ; 1 intervention group (n=10) and 2 control groups (n=20), and 1 negative high-quality trial 38 ; 1 intervention group (n=30) and 2 control groups (n=60)] and limited on CO 2 laser pain [1 low-quality trial ; 1 intervention group (n=10) and 1 control group (n=10)].
The inefficacy of this TENS mode is moderate on electrical pain [2 low-quality trials 62, 63 ; 2 intervention groups (n=18) and 2 control groups (n=18)] and limited on ischemic pain [1 low-quality trial 31 ; 1 intervention group (n=12) and 1 control group (n=12)]. The efficacy of conventional TENS varies widely from strong evidence of efficacy to strong evidence of inefficacy across different experimental pain models. There is strong evidence of efficacy for this mode of TENS for pressure pain from 8 positive trials [7 high quality 36, 38, 41, 43, 45, 47, 48 and 1 low quality 49 ; 14 intervention groups (n=213) and 12 control groups (n=207), and 4 high-quality negative trials 34, 41, 44, 46 ; 5 intervention groups (n=52) and 5 control groups (n=50)]. There is moderate evidence of efficacy for thermal pain [3 low-quality positive trials 50, 52, 53 ; 5 intervention groups (n=46) and 3 control groups (n=46), and 1 low-quality negative trial 49 ; 1 intervention group (n=16) and 1 control group (n=16)]. There is conflicting evidence of efficacy for cold pressor pain [4 positive trials [55] [56] [57] [58] : 1 high quality 55 ; with 12 intervention groups (n=139) and 5 control groups (n=55), and 2 negative trials 26, 54 : 1 high quality 26 ; with 2 intervention groups (n=19) and 3 control groups (n=29)]. Finally, there is limited evidence of efficacy for capsaicin [1 low-quality trial 64 ; 1 intervention group (n=8) and 1 control group (n=8)].
There is strong evidence of inefficacy for this mode of TENS for ischemic pain [3 trials of which 2 are high quality 26, 33 and 1 low quality 27 ; 3 intervention groups (n=26) and 5 control groups (n=42)] and also the RIII pain model [2 high-quality trials 59, 60 ; 4 intervention groups (n=44) and 2 control groups (n=22)]. There is limited Other TENS modes: All trials investigated local (segmental) stimulation. Four adequately powered trials also systematically investigated the effect of different TENS parameter combinations (stimulation site, frequency, and intensity). [37] [38] [39] [40] The only positive effect reported with a remote (extrasegmental) application was in combination with low-frequency, high-intensity TENS 38 [1 high-quality trial; 1 intervention group (n=30) and 2 control groups (n=60)]. Positive effects were also reported with several concurrent (dual-site) TENS combinations. [37] [38] [39] Two highquality trials 37, 38 had n=30 per intervention group and 2 control groups (n=60), and 1 high-quality trial 39 had intervention groups of n=26 and 2 control groups (n=52). Therefore, limited evidence of efficacy exists for these specific TENS parameter combinations. Similarly, there is limited evidence of inefficacy for the other TENS parameter combinations investigated in these studies.
Magnitude of Response
Effect sizes of positive trials are reported in Table 4 . The majority of positive trials investigating conventional TENS had varying effect sizes compared with control and placebo during the TENS period. Six trials reported 17 large effect sizes during the stimulation period. Two trials were high quality 47, 55 and 4 were low quality 50, 52, 56, 57 ; 17 intervention groups (n=143) and 6 control groups (n=71). The effect size was inconsistent and irregular (in only 4 trials) in the monitoring period. Only 1 high-quality trial 55 [1 intervention group (n=7) and 1 control group (n=7)] reported a large effect size for conventional TENS in the 37 ; 2 intervention groups (n=42) and 4 control groups (n=104)] and concurrent TENS [when high-intensity stimulation was used; 3 highquality trials 37-39 reported 9 effect sizes; 5 intervention groups (n=138) and 6 control groups (n=172)] during the TENS period. In the monitoring period, a medium effect size was reported for intense TENS [2 trials 37,58 reported 3 effect sizes; 3 intervention groups (n=60) and 2 control groups (n=42)], and a large effect size was reported for concurrent TENS parameters [when high-intensity stimulation was combined with different frequencies at each site; 1 high-quality trial 39 ; 2 intervention groups (n=52) and 2 control groups (n=60)].
DISCUSSION
This comprehensive review of laboratory-based RCTs has clearly shown that the efficacy of TENS varies across different TENS parameter combinations and experimental pain models. Specifically, from the evidence reported the following conclusions can be made:
There is strong evidence for the efficacy of: Conventional TENS applied in pressure pain models There is moderate evidence for the efficacy of: Intense TENS irrespective of experimental pain model and Conventional TENS applied in thermal pain models. There is conflicting evidence for the efficacy of: TENS irrespective of experimental pain model and parameter combinations, Low-intensity, low-frequency, local TENS applied in ischemic pain models, Acupuncture-like TENS irrespective of experimental pain model, Acupuncture-like TENS applied in pressure pain models, Conventional TENS irrespective of experimental pain model, and Conventional TENS applied in cold pressor pain models. There is limited evidence for the efficacy of: Intense TENS applied in pressure pain models, Intense TENS applied in cold pressor pain models, Intense TENS applied in CO 2 laser pain models, Low-intensity, low-frequency local TENS applied in caspsaicin pain models, Acupuncture-like TENS applied in CO 2 laser pain models, Conventional TENS applied in caspsaicin pain models, and High-intensity, concurrent groups on pressure pain (where high intensity is applied locally or at both sites, and the frequency is low or high) ( Table 3 ). There is strong evidence for the inefficacy of: Low-intensity, low-frequency, local TENS irrespective of experimental pain model, Low-intensity, low-frequency, local TENS applied in pressure pain models, Low-intensity, low-frequency, local TENS applied in the RIII pain model, Conventional TENS applied in ischemic pain models, and Conventional TENS applied in the RIII pain model. There is moderate evidence for the inefficacy of: Inappropriate TENS delivery, Low-intensity, low-frequency, local TENS applied in cold pressor pain models, and Acupuncture-like TENS applied in ischemic pain models. There is limited evidence for the inefficacy of: Intense TENS applied in ischemic pain models, Low-intensity, low frequency, local TENS applied in DOMS, Low-intensity, low frequency, local TENS applied in thermal pain models, Acupuncture-like TENS in ischemic pain models, Conventional TENS applied in DOMS, Conventional TENS applied in electrical pain models, Low-intensity remote TENS parameters in pressure pain models (regardless of frequency), Low-intensity, concurrent TENS parameters in pressure pain models (except high frequency), and High-intensity, remote TENS in pressure pain models (high frequency and alternating frequency). Strong evidence of efficacy was reported in this review for the effects of conventional TENS on pressure pain. As regards the magnitude and timing of response of conventional TENS, there is limited evidence of a large effect during TENS. This is because only one 47 of trials that reported large effects during TENS stimulation (as opposed to poststimulation) used the pressure pain model. This hypoalgesic profile may be partly explained by the activation of segmental Ab fibers inducing the "pain gate," 5 as a rapid reduction of hypoalgesia poststimulation is associated with this neuronal mechanism. This painmodulating mechanism was the original premise for the development of TENS and this selection of parameters. Pressure algometry induces pain mediated by Ad and C afferent fibers from skin and muscles and has been described as an experimental parallel to palpation in clinical practice. 115 This finding therefore provides evidence concerning the effects of TENS on muscle hyperalgesia and also cutaneous pain sensitivity.
Strong evidence of efficacy of conventional TENS in the pressure pain model contrasts the strong evidence of inefficacy of conventional TENS in ischemic pain and the RIII pain models. Together these gradings are responsible for the overall conflicting evidence of efficacy for this TENS mode. It is possible that either conventional TENS is not efficacious on these latter pain models or TENS irrespective of TENS parameters is not efficacious on these pain models. From the evidence reported in this review, it would seem that it may be that TENS irrespective of TENS parameters used is not efficacious on the ischemic and RIII pain model. All the levels of evidence for these pain models state that TENS modes have no effect (have inefficacy) apart from 1 TENS mode that was conflicting.
The lack of efficacy of low-intensity, low-frequency, local TENS may be explained in terms of an insufficient stimulus to active nerve fibers. The resistance of nerve fibers to the transmission of impulses is related to both their diameter and presence of myelin; the threshold for activation and conduction speed is inversely proportional to diameter, and myelinated fibers conduct faster than unmyelinated fibers. 116 Large myelinated Ab fibers, therefore, have a lower threshold for activation and transmit nervous impulses at a faster rate than Ad fibers and so are preferentially activated by high-frequency, low-intensity stimulation. Low-frequency stimulation is best suited for activating Ad or C fibers because of their slow conduction speed and a long refractory period (although it is acknowledged that low-frequency stimulation can activate Ab fibers, low-frequency stimulation is best suited for activating Ad or C fibers). Ad and C fibers, however, have a higher threshold for activation and thus require a relatively higher intensity of stimulation (hence high-intensity, lowfrequency acupuncture-like TENS).
Moderate evidence of efficacy was reported for intense TENS (irrespective of experimental pain model), with medium-to-large effect sizes calculated for positive trials both during the TENS period and in the monitoring period. A reduction in sensory nerve impulse transmission and inhibition of spinothalamic tract cells may underlie the hypoalgesic effects observed with this mode of TENS. 117 The poststimulation hypoalgesic effects observed would be in accordance with mechanisms associated with the descending opioid system 7, 8 and long-term depression of nociceptive pathways. 6 Moderate evidence was also found regarding the lack of effect of inappropriate TENS doses where parameters included just perceptible intensities or had a small pulse duration. This finding underpins the importance of appropriate parameter selection 22, 118 and may underlie the results of negative trials (including clinical trials) that, although methodologically robust, use inadequate stimulation dosages of TENS.
This systematic review evidence found conflicting evidence for conventional TENS and acupuncture-like TENS. The conflicting nature of the evidence has been partly explained by the experimental pain model used. However, limitations in the reporting of the RCTs should be noted. Twenty-four of the trials in this review were low quality ( Table 2 ). The majority of these low-quality trials investigated conventional TENS using cold pressor, electrical, and ischemic pain models. With inadequate methodology, the extent and direction of bias is often impossible to predict. 17 This issue may also underpin the conflicting evidence of efficacy found in relation to this TENS mode and some of these pain models reported in this review.
High-intensity stimulation parameters (in combination with specific frequency and stimulation site combinations), however, have been shown in this review to have higher rankings of supporting evidence and more favorable hypoalgesic profiles in terms of both magnitude and longevity of response. Limited evidence of efficacy for novel TENS parameters was shown in this review. Concurrent TENS parameter combinations with highintensity stimulation and different frequencies at each site were a prerequisite for medium or large effect sizes both during the TENS period and in monitoring. These findings are in accordance with the proposed pain-modulating mechanisms of frequency-specific opioid inhibition. That is, the employment of both low and high frequencies within stimulation dosages may result in the release of all 3 opioid peptides in the central nervous system 119, 120 and result in maximal hypoalgesia. However, conclusions regarding TENS parameter interactions are based on the utilization of the subjective descriptions of intensity (as described by study participants). This may be because the mA applied may be affected by many factors such as electrode size, skin conductance, and individual sensitivity. These subjective descriptions of intensity are used in clinical practice. Few trials reported the mA applied or whether a muscle contraction was achieved. It is encouraging, however, that recent trials are high quality, [36] [37] [38] [39] [40] [41] [42] 44 testing novel TENS parameters, and are providing mA data.
TENS is currently recommended in the UK by the National Institute for Health and Clinical Excellence for the management of pain in osteoarthritis. 121 This guidance recommends an assessment visit with a health professional with proper training in the selection of conventional TENS parameters, although people with osteoarthritis are encouraged to experiment with intensities and duration of application if relief of symptoms is not achieved. 121 In contrast, TENS is not currently recommended by National Institute for Health and Clinical Excellence for the early management of persistent nonspecific low back pain. 122 This guidance was based on the results of 3 RCTs that investigated different TENS parameters. This confusion may arise from the lack of consistency in clinical trials in the selection of effective TENS parameters. Future clinical RCTs should consider the recommendations made in this review regarding TENS dose-specific responses on experimental pain trials in healthy humans.
This review has a number of strengths and also some limitations. Systematic searches of the literature were performed using electronic databases and hand searching in an attempt to locate all eligible RCTs. Standardized criteria were used to define appropriate TENS delivery and TENS parameters to allow appropriate comparisons between RCTs. Categorizing trials according to methodologic quality permitted the rigor of the evidence to be established when recommendations were being made. Effect sizes calculated at available time-points also allowed the hypoalgesic profiles (in terms of magnitude and longevity of response) of different TENS parameter combinations to be characterized.
Although a meta-analysis was not appropriate for this review because of the variation in study characteristics, outcome measures, and pain models used, evidence was graded based on criteria that ranked levels of efficacy. These criteria were dependent on the number of RCTs found and the number of RCTs that found significant differences between TENS and control groups. Although efforts were made to locate trials, it is conceivable that not all trials were found. The ranking criteria also took no account of differential weights given to each trial (for example, the weight given to an adequately powered highquality RCT and an unpowered high-quality RCT was equal). A trial was deemed to be positive if a significant difference between TENS and an inactive control group was reported at any time point in a trial. Evidence regarding TENS efficacy should therefore be interpreted with regard to the time point reported (during TENS or in the poststimulation monitoring period) and the magnitude of effect (effect size).
In this review, the efficacy of TENS was compared with inactive control groups. It has recently been argued that TENS trials cannot be blinded because a prerequisite of TENS is strong sensations and a prerequisite of placebo (no current) is no TENS-related sensation. 36 Other researchers have advocated the use of "barely perceptible" TENS as a placebo. 123 The validity of the placebo used in RCTs in this review depends on the stance taken as to what constitutes a placebo condition. It is recommended that future TENS trials report the success of blinding (whether participants believe they received placebo or active TENS) to be able to judge the credibility of the methods used. In addition, one needs to be cautious in making definitive inferences about the relative effectiveness of different parameter combinations on the indirect basis of their individual efficacy against an inactive treatment. Authors of included RCTs were not contacted for further information and a language restriction was also imposed on this review to RCTs in English. Searches identified a trial written in Swedish; however, it would have been ineligible for inclusion (as identified from the abstract).
CONCLUSIONS
This review highlights the importance of TENS parameter combinations selection (intensity, frequency, and stimulations site) and the type of experimental pain model in obtaining hypoalgesic effects. Overall, there is conflicting evidence of TENS efficacy (irrespective of parameters) compared with inactive control groups. In general, intense TENS has the strongest evidence of efficacy (moderate efficacy) irrespective of experimental pain model. Conventional TENS has strong evidence of efficacy in pressure pain models and strong evidence of inefficacy in ischemic pain models and the RIII pain model; hence the overall conflicting evidence for this TENS mode. Limited evidence of hypoalgesia exists for some novel parameters that showed desirable hypoalgesic profiles (in terms of both magnitude and longevity of response). Specifically, highintensity, concurrent TENS (with different frequencies at each site) showed large effects during and poststimulation. Low-intensity, low-frequency, local TENS has strong evidence of inefficacy irrespective of experimental pain model. Inappropriate TENS (using barely perceptible intensities) has moderate evidence of inefficacy. These recommendations should be interpreted alongside trial quality; about half (20 of 43) of the trials were high quality. The majority of low-quality trials investigated conventional TENS. The findings of this review permit tentative suggestions regarding efficacious parameter selection of TENS for use in clinical practice and suggest standardized doses for testing in future clinical trials.
